In a report issued 6/26/2017 Morgan Stanley raised the stock price target of Portola Pharmaceuticals (NDAQ:PTLA) from $50.00 to $70.00 reporting a possible upside of 0.23%.
On 5/10/2017, Oppenheimer released a statement on Portola Pharmaceuticals (NDAQ:PTLA) upped the target price from $0.00 to $46.00. At the time, this indicated a possible upside of 0.10%.
Showing a price of $56.96, Portola Pharmaceuticals (NDAQ:PTLA) traded -0.82% lower on the day. With the last stock price up 37.83% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same time period. PTLA has recorded a 50-day moving average of $60.48 and a two hundred day average of $45.66. Volume of trade was down over the average, with 599,305 shares of PTLA changing hands under the typical 1,037,170
Portola Pharmaceuticals has a 52 week low of $15.68 and a 52 week high of $67.10 Portola Pharmaceuticals’s market capitalization is presently $0.
A total of 5 analysts have released a report on Portola Pharmaceuticals. Two analysts rating the stock a strong buy, 4 firms rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $47.80.
General Company Details For Portola Pharmaceuticals (NDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
The post Morgan Stanley covered Portola Pharmaceuticals (NDAQ:PTLA), upping its stock price target to $70.00 today appeared first on Octafinance.